REG - GSK PLC - Director/PDMR Shareholding
17/04/2025 15:30
For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250417:nRSQ5221Fa&default-theme=true
RNS Number : 5221F GSK PLC 17 April 2025
GSK plc (the 'Company')
Transaction notification
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Emma Walmsley
b) Position/status Chief Executive Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 10 April 2025 on Ordinary Shares held in
the Company's Deferred Annual Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£12.7500 1,304
£12.7500 1,702
£12.7500 1,924
d) Aggregated information
Aggregated volume Price 4,930
£12.7500
e) Date of the transaction 2025-04-16
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Julie Brown
b) Position/status Chief Financial Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 10 April 2025 on Ordinary Shares held in
the Company's Deferred Annual Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£12.7500 854
£12.7500 734
d) Aggregated information
Aggregated volume Price 1,588
£12.7500
e) Date of the transaction 2025-04-16
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Diana Conrad
b) Position/status Chief People Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 10 April 2025 on Ordinary Shares held in
the Company's Deferred Annual Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£12.7500 191
£12.7500 485
£12.7500 309
d) Aggregated information
Aggregated volume Price 985
£12.7500
e) Date of the transaction 2025-04-16
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name James Ford
b) Position/status SVP and Group General Counsel, Legal and Compliance
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 10 April 2025 on Ordinary Shares held in
the Company's Deferred Annual Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£12.7500 298
£12.7500 491
£12.7500 301
d) Aggregated information
Aggregated volume Price 1,090
£12.7500
e) Date of the transaction 2025-04-16
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Sally Jackson
b) Position/status SVP, Global Communications and CEO Office
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 10 April 2025 on Ordinary Shares held in
the Company's Deferred Annual Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£12.7500 167
£12.7500 304
£12.7500 187
d) Aggregated information
Aggregated volume Price 658
£12.7500
e) Date of the transaction 2025-04-16
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Luke Miels
b) Position/status Chief Commercial Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 10 April 2025 on Ordinary Shares held in
the Company's Deferred Annual Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£12.7500 458
£12.7500 914
£12.7500 726
d) Aggregated information
Aggregated volume Price 2,098
£12.7500
e) Date of the transaction 2025-04-16
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Shobie Ramakrishnan
b) Position/status Chief Digital and Technology Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument American Depositary Shares ('ADSs')
ISIN: US37733W2044
b) Nature of the transaction Increase in notional interest in ADSs following the re-investment of dividends
paid to shareholders on 10 April 2025 on ADSs held in the Company's Deferred
Annual Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
$33.6000 134
$33.6000 222
$33.6000 143
d) Aggregated information
Aggregated volume Price 499
$33.6000
e) Date of the transaction 2025-04-16
f) Place of the transaction New York Stock Exchange (XNYS)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name David Redfern
b) Position/status President, Corporate Development
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 10 April 2025 on Ordinary Shares held in
the Company's Deferred Annual Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£12.7500 265
£12.7500 581
£12.7500 419
d) Aggregated information
Aggregated volume Price 1,265
£12.7500
e) Date of the transaction 2025-04-16
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Regis Simard
b) Position/status President, Global Supply Chain
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 10 April 2025 on Ordinary Shares held in
the Company's Deferred Annual Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£12.7500 388
£12.7500 337
£12.7500 700
d) Aggregated information
Aggregated volume Price 1,425
£12.7500
e) Date of the transaction 2025-04-16
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Philip Thomson
b) Position/status President, Global Affairs
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 10 April 2025 on Ordinary Shares held in
the Company's Deferred Annual Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£12.7500 236
£12.7500 391
£12.7500 220
d) Aggregated information
Aggregated volume Price 847
£12.7500
e) Date of the transaction 2025-04-16
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Deborah Waterhouse
b) Position/status CEO, ViiV Healthcare and President, Global Health, GSK
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 10 April 2025 on Ordinary Shares held in
the Company's Deferred Annual Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£12.7500 365
£12.7500 537
£12.7500 606
d) Aggregated information
Aggregated volume Price 1,508
£12.7500
e) Date of the transaction 2025-04-16
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Tony Wood
b) Position/status Chief Scientific Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 10 April 2025 on Ordinary Shares held in
the Company's Deferred Annual Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£12.7500 340
£12.7500 254
£12.7500 746
d) Aggregated information
Aggregated volume Price 1,340
£12.7500
e) Date of the transaction 2025-04-16
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Emma Walmsley
b) Position/status Chief Executive Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid
to shareholders on 10 April 2025 on Ordinary Shares held in the Company's
Performance Share Plan subject to a 2-year holding period
c) Price(s) and volume(s) Price(s) Volume(s)
£12.7500 11,184.930
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2025-04-16
f) Place of the transaction London Stock Exchange (XLON)
d)
Aggregated information
Aggregated volume Price
N/A (single transaction)
e)
Date of the transaction
2025-04-16
f)
Place of the transaction
London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Dr Hal Barron
b) Position/status Non-Executive Director
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument American Depositary Shares ('ADSs')
ISIN: US37733W2044
b) Nature of the transaction Acquisition of ADSs following the re-investment of dividends paid to
shareholders on 10 April 2025
c) Price(s) and volume(s) Price(s) Volume(s)
$35.9948 3603.574
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2025-04-15
f) Place of the transaction New York Stock Exchange (XNYS)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name James Ford
b) Position/status SVP and Group General Counsel, Legal and Compliance
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument American Depositary Shares ('ADSs')
ISIN: US37733W2044
b) Nature of the transaction Acquisition of ADSs following the re-investment of dividends paid to
shareholders on 10 April 2025
c) Price(s) and volume(s) Price(s) Volume(s)
$35.9948 363.602
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2025-04-15
f) Place of the transaction New York Stock Exchange (XNYS)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Shobie Ramakrishnan
b) Position/status Chief Digital and Technology Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument American Depositary Shares ('ADSs')
ISIN: US37733W2044
b) Nature of the transaction Acquisition of ADSs following the re-investment of dividends paid to
shareholders on 10 April 2025
c) Price(s) and volume(s) Price(s) Volume(s)
$35.9948 437.999
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2025-04-15
f) Place of the transaction New York Stock Exchange (XNYS)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHSFEFDWEISEILRecent news on GSK
See all newsREG - GSK PLC - Transaction in Own Shares
AnnouncementREG - GSK PLC - Director/PDMR Shareholding
AnnouncementREG - GSK PLC - Total Voting Rights
AnnouncementREG - GSK PLC - Transaction in Own Shares
AnnouncementREG - GSK PLC - Nucala MATINEE data in COPD published in NEJM
Announcement